Table 3.

Multivariate analysis evaluating factors predicting anti- SARS-CoV-2 positive serology

Variables	P	Odds ratio	95% CI
Analysis of entire cohort (n = 149)
Age in time of vaccination, y	.01	2.95	1.29-6.73
Prior exposure to anti CD20 abs	.005	0.05	0.06-0.39
Analysis of patients treated with anti-CD20 abs (n = 121)
ALC >0. 9 × 103/µL	.036	2.82	1.07-7.4
Time since last anti-CD20 abs (mo)	<.001	1.092	1.04-1.14
Histology: a-B-NHL vs i-B-NHL	.082	2.439	0.89-6.67

Factors included in the analysis of the entire cohort were age, ALC, disease type (a-B-NHL vs i-B-NHL) and prior exposure to anti-CD20 Abs. Factors included in analyses of patients treated with anti-CD20 Abs were age, ALC, disease type (a-B-NHL vs i-B-NHL), and time since last treatment with anti-CD20 Abs.